Definitive Healthcare (NASDAQ:DH) Sees Strong Trading Volume

Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) shares saw strong trading volume on Tuesday . 1,461,992 shares changed hands during mid-day trading, an increase of 157% from the previous session's volume of 569,377 shares.The stock last traded at $7.21 and had previously closed at $7.09.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Canaccord Genuity Group downgraded Definitive Healthcare from a "buy" rating to a "hold" rating in a research report on Friday, January 5th. Stifel Nicolaus cut their price target on Definitive Healthcare from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Wednesday, January 17th. Canaccord Genuity Group boosted their price target on Definitive Healthcare from $9.00 to $10.00 and gave the company a "hold" rating in a research note on Thursday, February 29th. Barclays boosted their price target on Definitive Healthcare from $10.00 to $11.00 and gave the company an "equal weight" rating in a research note on Friday, March 1st. Finally, Needham & Company LLC cut Definitive Healthcare from a "buy" rating to a "hold" rating in a research note on Wednesday, January 17th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Definitive Healthcare has an average rating of "Hold" and a consensus target price of $11.31.

Definitive Healthcare Stock Up 3.1 %

The firm has a market capitalization of $861.04 million, a price-to-earnings ratio of -4.11, a P/E/G ratio of 10.89 and a beta of 1.39. The stock has a fifty day moving average of $8.50 and a two-hundred day moving average of $8.33. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.31 and a quick ratio of 2.31.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by ($0.02). Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. The business had revenue of $65.93 million for the quarter, compared to analyst estimates of $66.01 million. Sell-side analysts anticipate that Definitive Healthcare Corp. will post 0.07 earnings per share for the current year.

Institutional Trading of Definitive Healthcare

Large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its stake in shares of Definitive Healthcare by 11.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,090,136 shares of the company's stock valued at $8,710,000 after buying an additional 113,963 shares during the period. Eagle Asset Management Inc. lifted its position in Definitive Healthcare by 7.5% in the 3rd quarter. Eagle Asset Management Inc. now owns 784,230 shares of the company's stock valued at $6,266,000 after acquiring an additional 54,590 shares in the last quarter. Raymond James & Associates lifted its position in Definitive Healthcare by 24.2% in the 3rd quarter. Raymond James & Associates now owns 650,327 shares of the company's stock valued at $5,196,000 after acquiring an additional 126,613 shares in the last quarter. Victory Capital Management Inc. lifted its position in Definitive Healthcare by 68.4% in the 3rd quarter. Victory Capital Management Inc. now owns 269,433 shares of the company's stock valued at $2,153,000 after acquiring an additional 109,463 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Definitive Healthcare by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,331,543 shares of the company's stock valued at $34,609,000 after acquiring an additional 254,726 shares in the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.